Financial Ratios Bruker Corporation
Equities
BRKR
US1167941087
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.98 USD | -0.82% |
|
-1.99% | -18.39% |
| Nov. 24 | Bruker Corporation acquired AST Revolution, LLC from Indaba Capital Management, L.P. | CI |
| Nov. 24 | Bruker Buys AST Revolution | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.71 | 7.95 | 7.86 | 7.7 | 5.1 | |||||
Return on Total Capital | 8.79 | 11.97 | 11.61 | 11.56 | 7.48 | |||||
Return On Equity % | 16.88 | 27.25 | 26.93 | 33.67 | 7.05 | |||||
Return on Common Equity | 16.9 | 27.28 | 27.16 | 34.3 | 7.16 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 47.52 | 50.2 | 51.65 | 51.25 | 50 | |||||
SG&A Margin | 23.74 | 23.28 | 24.04 | 24.61 | 26.51 | |||||
EBITDA Margin % | 17.43 | 21.31 | 21.55 | 20.21 | 17.65 | |||||
EBITA Margin % | 15.19 | 19.17 | 19.5 | 17.92 | 15.13 | |||||
EBIT Margin % | 13.39 | 17.62 | 18.04 | 16.33 | 12.19 | |||||
Income From Continuing Operations Margin % | 8.12 | 11.61 | 11.8 | 14.45 | 3.38 | |||||
Net Income Margin % | 7.94 | 11.46 | 11.72 | 14.41 | 3.36 | |||||
Net Avail. For Common Margin % | 7.94 | 11.46 | 11.72 | 14.41 | 3.36 | |||||
Normalized Net Income Margin | 7.58 | 10.42 | 10.78 | 9.67 | 7.29 | |||||
Levered Free Cash Flow Margin | 10.66 | 8.2 | 7.26 | 9.84 | 8.44 | |||||
Unlevered Free Cash Flow Margin | 11.11 | 8.57 | 7.65 | 10.19 | 9.33 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.68 | 0.72 | 0.7 | 0.75 | 0.67 | |||||
Fixed Assets Turnover | 4.76 | 5.21 | 5.04 | 4.82 | 4.47 | |||||
Receivables Turnover (Average Receivables) | 5.06 | 5.74 | 5.06 | 5.32 | 5.42 | |||||
Inventory Turnover (Average Inventory) | 1.64 | 1.72 | 1.62 | 1.63 | 1.65 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.43 | 2.63 | 2.31 | 1.8 | 1.6 | |||||
Quick Ratio | 1.41 | 1.74 | 1.31 | 0.93 | 0.7 | |||||
Operating Cash Flow to Current Liabilities | 0.42 | 0.3 | 0.3 | 0.29 | 0.2 | |||||
Days Sales Outstanding (Average Receivables) | 72.33 | 63.6 | 72.07 | 68.6 | 67.54 | |||||
Days Outstanding Inventory (Average Inventory) | 222.72 | 212.54 | 225.23 | 223.31 | 221.35 | |||||
Average Days Payable Outstanding | 39.97 | 42.12 | 45.26 | 43.11 | 44.84 | |||||
Cash Conversion Cycle (Average Days) | 255.08 | 234.03 | 252.04 | 248.81 | 244.06 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 100 | 130.7 | 113.32 | 99.51 | 123.69 | |||||
Total Debt / Total Capital | 50 | 56.65 | 53.12 | 49.88 | 55.3 | |||||
LT Debt/Equity | 97.15 | 118.15 | 110.22 | 89.29 | 120.14 | |||||
Long-Term Debt / Total Capital | 48.57 | 51.21 | 51.67 | 44.75 | 53.71 | |||||
Total Liabilities / Total Assets | 68.05 | 70.28 | 68.66 | 66.74 | 68.74 | |||||
EBIT / Interest Expense | 18.48 | 29.8 | 28.35 | 29.52 | 8.57 | |||||
EBITDA / Interest Expense | 26.06 | 38.07 | 35.38 | 38.96 | 13.59 | |||||
(EBITDA - Capex) / Interest Expense | 19.31 | 31.64 | 27.35 | 32.45 | 11.18 | |||||
Total Debt / EBITDA | 2.6 | 2.6 | 2.25 | 2.2 | 3.45 | |||||
Net Debt / EBITDA | 0.63 | 0.45 | 1.09 | 1.42 | 3.15 | |||||
Total Debt / (EBITDA - Capex) | 3.5 | 3.13 | 2.91 | 2.64 | 4.19 | |||||
Net Debt / (EBITDA - Capex) | 0.84 | 0.54 | 1.41 | 1.7 | 3.83 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -4.11 | 21.66 | 4.67 | 17.14 | 13.56 | |||||
Gross Profit, 1 Yr. Growth % | -6.75 | 28.52 | 7.69 | 16.24 | 10.78 | |||||
EBITDA, 1 Yr. Growth % | -11.65 | 48.69 | 5.95 | 9.85 | -1.64 | |||||
EBITA, 1 Yr. Growth % | -14.93 | 53.53 | 6.61 | 7.62 | -5 | |||||
EBIT, 1 Yr. Growth % | -15.95 | 60.13 | 7.26 | 6.05 | -16.11 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -18.48 | 73.85 | 6.38 | 43.55 | -73.44 | |||||
Net Income, 1 Yr. Growth % | -19.98 | 75.6 | 7.04 | 44.03 | -73.53 | |||||
Normalized Net Income, 1 Yr. Growth % | -18.9 | 67.12 | 8.49 | 5.46 | -15.34 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -19.05 | 77.45 | 9.94 | 45.73 | -73.83 | |||||
Accounts Receivable, 1 Yr. Growth % | -7.14 | 22.78 | 15.33 | 7.95 | 15.79 | |||||
Inventory, 1 Yr. Growth % | 19.94 | 2.57 | 12.67 | 21.02 | 10.28 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 24.54 | 0.67 | 15.49 | 28.47 | 17.85 | |||||
Total Assets, 1 Yr. Growth % | 10.01 | 19.71 | -1.05 | 17.67 | 36.63 | |||||
Tangible Book Value, 1 Yr. Growth % | 8.17 | 26.11 | -25.79 | 20.45 | -237.6 | |||||
Common Equity, 1 Yr. Growth % | 6 | 11.37 | 4.04 | 23.65 | 29.33 | |||||
Cash From Operations, 1 Yr. Growth % | 55.67 | -14.99 | -2.83 | 27.59 | -28.22 | |||||
Capital Expenditures, 1 Yr. Growth % | 33.15 | -5.35 | 40.43 | -17.26 | 7.86 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 70.3 | -6.34 | -7.28 | 58.84 | -3.61 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 64.33 | -6.11 | -6.42 | 55.88 | 2.97 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 25 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 2.4 | 8.01 | 12.84 | 10.73 | 15.34 | |||||
Gross Profit, 2 Yr. CAGR % | 2.07 | 10.14 | 17.69 | 11.92 | 13.5 | |||||
EBITDA, 2 Yr. CAGR % | 0.94 | 16.44 | 25.59 | 7.95 | 4.13 | |||||
EBITA, 2 Yr. CAGR % | -0.36 | 16.3 | 28.04 | 7.19 | 1.32 | |||||
EBIT, 2 Yr. CAGR % | -1.67 | 18.31 | 31.18 | 6.74 | -5.46 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -5.57 | 19.04 | 35.99 | 23.58 | -38.26 | |||||
Net Income, 2 Yr. CAGR % | -6.29 | 18.54 | 37.1 | 24.16 | -38.25 | |||||
Normalized Net Income, 2 Yr. CAGR % | -3.57 | 18.89 | 34.79 | 6.85 | -5.46 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -5.41 | 19.85 | 39.68 | 26.58 | -38.24 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.79 | 6.78 | 19 | 11.53 | 11.79 | |||||
Inventory, 2 Yr. CAGR % | 16.56 | 10.92 | 7.5 | 16.77 | 15.52 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.79 | 11.97 | 7.83 | 21.81 | 23.04 | |||||
Total Assets, 2 Yr. CAGR % | 19.68 | 14.76 | 8.84 | 7.91 | 26.8 | |||||
Tangible Book Value, 2 Yr. CAGR % | 1.17 | 16.8 | -3.26 | -5.46 | 28.74 | |||||
Common Equity, 2 Yr. CAGR % | 3.54 | 8.65 | 7.65 | 13.42 | 26.46 | |||||
Cash From Operations, 2 Yr. CAGR % | 17.72 | 15.04 | -9.12 | 11.34 | -4.3 | |||||
Capital Expenditures, 2 Yr. CAGR % | 40.56 | 12.26 | 15.29 | 7.79 | -5.53 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 6.82 | 30.35 | -6.75 | 21.49 | 23.85 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 6.82 | 27.89 | -6.21 | 20.91 | 26.81 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 11.8 | 11.8 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4.02 | 8.45 | 6.88 | 14.26 | 11.66 | |||||
Gross Profit, 3 Yr. CAGR % | 4.75 | 10.22 | 9.31 | 17.21 | 11.54 | |||||
EBITDA, 3 Yr. CAGR % | 4.98 | 14.85 | 12.79 | 20.11 | 4.95 | |||||
EBITA, 3 Yr. CAGR % | 4.42 | 15.08 | 12.93 | 20.83 | 3.29 | |||||
EBIT, 3 Yr. CAGR % | 4.14 | 15.69 | 14.46 | 22.2 | -1.16 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 26.2 | 15.74 | 14.66 | 38.47 | -25.98 | |||||
Net Income, 3 Yr. CAGR % | 26.15 | 15.53 | 14.57 | 39.37 | -25.82 | |||||
Normalized Net Income, 3 Yr. CAGR % | 4.18 | 15.83 | 15.27 | 24.04 | -0.77 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 27.68 | 16.66 | 16.46 | 41.67 | -25.15 | |||||
Accounts Receivable, 3 Yr. CAGR % | 5.7 | 6.52 | 9.56 | 15.16 | 12.92 | |||||
Inventory, 3 Yr. CAGR % | 12.5 | 11.69 | 11.5 | 11.83 | 14.57 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.21 | 19.86 | 13.13 | 14.31 | 20.47 | |||||
Total Assets, 3 Yr. CAGR % | 16.1 | 19.69 | 9.23 | 11.71 | 16.74 | |||||
Tangible Book Value, 3 Yr. CAGR % | -4.53 | 8.88 | 0.41 | 4.07 | 7.14 | |||||
Common Equity, 3 Yr. CAGR % | 9.84 | 6.09 | 7.09 | 12.74 | 18.5 | |||||
Cash From Operations, 3 Yr. CAGR % | 29.1 | 5.62 | 8.74 | 1.76 | -3.81 | |||||
Capital Expenditures, 3 Yr. CAGR % | 30.54 | 23.2 | 20.96 | 3.22 | 7.82 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 67.93 | 2.24 | 16.3 | 11.36 | 12.87 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 59.57 | 2.32 | 15.19 | 11.1 | 15 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 7.72 | 7.72 | 7.72 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 4.12 | 8.46 | 7.46 | 9.36 | 10.19 | |||||
Gross Profit, 5 Yr. CAGR % | 5.29 | 9.92 | 9.73 | 10.88 | 10.96 | |||||
EBITDA, 5 Yr. CAGR % | 7.99 | 14.47 | 12.73 | 11.99 | 9.35 | |||||
EBITA, 5 Yr. CAGR % | 8.23 | 15.09 | 13.23 | 11.8 | 8.25 | |||||
EBIT, 5 Yr. CAGR % | 7.82 | 15.44 | 14.14 | 11.96 | 6.15 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 9 | 12.68 | 30.03 | 18.81 | -10.49 | |||||
Net Income, 5 Yr. CAGR % | 9.2 | 12.52 | 30.42 | 18.91 | -10.52 | |||||
Normalized Net Income, 5 Yr. CAGR % | 8.57 | 15.32 | 15.41 | 12.08 | 6.61 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.2 | 13.76 | 32.35 | 20.53 | -9.64 | |||||
Accounts Receivable, 5 Yr. CAGR % | 9.95 | 13.68 | 10.83 | 8.49 | 10.42 | |||||
Inventory, 5 Yr. CAGR % | 10.41 | 10.03 | 10.48 | 13.7 | 13.09 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 14.9 | 14.28 | 15.09 | 20.64 | 17 | |||||
Total Assets, 5 Yr. CAGR % | 12 | 15.08 | 13.14 | 14.83 | 15.94 | |||||
Tangible Book Value, 5 Yr. CAGR % | -4.59 | 1.33 | -4.03 | 2.9 | 10.91 | |||||
Common Equity, 5 Yr. CAGR % | 5.77 | 9.3 | 8.95 | 8.96 | 14.46 | |||||
Cash From Operations, 5 Yr. CAGR % | 7.71 | 16.64 | 12.19 | 7.87 | 3.32 | |||||
Capital Expenditures, 5 Yr. CAGR % | 23.23 | 19.92 | 24.21 | 16.79 | 9.57 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 0.11 | 18.05 | 32.64 | 9.46 | 19.47 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.18 | 16.95 | 28.94 | 9.31 | 19.9 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 0 | 4.56 | 4.56 | 4.56 |
- Stock Market
- Equities
- BRKR Stock
- Financials Bruker Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















